research use only

Guanfacine Hydrochloride Adrenergic Receptor agonist

Name: Guanfacine Hydrochloride
Brand: Selleck Chemicals
SKU: S4693
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S4693

Guanfacine Hydrochloride (Tenex, Intuniv) is a selective α2A-adrenoceptor agonist with anti-hypertensive effect.

Guanfacine Hydrochloride Adrenergic Receptor agonist Chemical Structure

Quality Control

Batch: S469301 DMSO]56 mg/mL]false]Ethanol]56 mg/mL]false]Water]30 mg/mL]false Purity: 99.98%

Cited in Nature Medicine for its top-tier quality
COA
SDS/MSDS
Datasheet

99.98

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Noradrenaline bitartrate monohydrate Fenoterol hydrobromide Medetomidine HCl Isoprenaline L-Adrenaline

Solubility

In vitro
Batch:

DMSO : 56 mg/mL (198.19 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 56 mg/mL

Water : 30 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	282.55	Formula	C₉H₉Cl₂N₃O.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	29110-48-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Guanfacine, Tenex, Intuniv			SMILES	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	α2A-adrenoceptor
References	[1] https://pubmed.ncbi.nlm.nih.gov/17173664/ [2] https://pubmed.ncbi.nlm.nih.gov/21931492/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07300956	NOT_YET_RECRUITING	Attention-Deficit/Hyperactivity Disorder (ADHD)	Children's Hospital Medical Center, Cincinnati	2026-02	PHASE4
NCT06629259	RECRUITING	Alcohol Use Disorder	Indiana University	2025-10-03	PHASE2
NCT06408246	RECRUITING	Depression	Stanford University	2026-03-03	PHASE2
NCT07757555	NOT_YET_RECRUITING	Postural Orthostatic Tachycardia Syndrome (POTS); Dysautonomia; Orthostatic Intolerance; Autonomic Nervous System Diseases	Johns Hopkins University	2026-08-15	EARLY_PHASE1
NCT03764098	RECRUITING	Alcohol Use	Yale University	2020-08-10	PHASE2
NCT06642181	RECRUITING	Mindfulness; Guanfacine; Opioid Use Disorder	Rutgers, The State University of New Jersey	2025-07-15	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):